Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Warrants (BFRGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BFRGW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 94.12% | Avg. Invested days 69 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 23211 | Beta - | 52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 |
52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Warrants
Company Overview
History and Background
Bullfrog AI Holdings, Inc. is a company focused on applying artificial intelligence to drug development and personalized medicine. Specific founding details and early milestones are limited in publicly available information. The company's warrants are derivatives tied to the underlying common stock.
Core Business Areas
- AI-Powered Drug Discovery: Utilizing AI and machine learning to accelerate the drug development process, identifying potential drug candidates, and predicting clinical trial outcomes.
- Personalized Medicine Solutions: Developing tools and platforms for personalized medicine, tailoring treatment plans based on individual patient characteristics.
- Data Analytics and Insights: Providing data analytics services and insights to pharmaceutical companies and healthcare providers.
Leadership and Structure
Details on the specific leadership team and organizational structure of Bullfrog AI Holdings, Inc. Warrants is tied to the common stock and subject to change with the underlying company. For information, refer to the underlying common stock information.
Top Products and Market Share
Key Offerings
- bfLEAPu2122: Bullfrog AI's proprietary platform for predictive analytics in drug development. Market share data is not readily available. Competitors include Schru00f6dinger, Exscientia, and Recursion Pharmaceuticals, which are all in the general AI-driven drug discovery space.
- Personalized Medicine Solutions: Developing customized treatment plans for individual patients. Market share data not available. Competitors are N-of-One (part of Qiagen), and Foundation Medicine (part of Roche).
Market Dynamics
Industry Overview
The AI-driven drug discovery market is experiencing significant growth, driven by the increasing complexity of drug development and the potential of AI to accelerate the process and reduce costs. The personalized medicine market is also expanding as healthcare becomes more data-driven.
Positioning
Bullfrog AI Holdings, Inc. aims to be a leader in AI-powered drug discovery and personalized medicine by offering its bfLEAPu2122 platform. However, the market is highly competitive, and its competitive advantages depend on the platform's performance and adoption.
Total Addressable Market (TAM)
The TAM for AI in drug discovery and personalized medicine is estimated to reach billions of dollars in the coming years. Bullfrog AI Holdings, Inc. Warrants' positioning depends on its ability to capture a significant share of this market through its innovative platform and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary AI platform (bfLEAPu2122)
- Expertise in data analytics and machine learning
- Focus on drug development and personalized medicine
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on the performance of its AI platform
- Limited market visibility and brand recognition
Opportunities
- Growing demand for AI-powered drug discovery solutions
- Increasing adoption of personalized medicine
- Partnerships with pharmaceutical companies and healthcare providers
Threats
- Intense competition from established AI companies
- Regulatory hurdles in drug development
- Data privacy and security concerns
Competitors and Market Share
Key Competitors
- SCHR
- RXRX
- XAI.PA
- NVS
- FMI
Competitive Landscape
Evaluate Bullfrog AI Holdings, Inc.'s advantages and disadvantages compared to its competitors, considering factors such as technology, market share, and financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Assess the company's historical growth based on its revenue, customer acquisition, and market expansion.
Future Projections: Analyze analyst estimates and market forecasts for Bullfrog AI Holdings, Inc. to project its future growth potential.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Bullfrog AI Holdings, Inc., such as new product launches, partnerships, and acquisitions.
Summary
Bullfrog AI Holdings, Inc. is a company focusing on AI-driven drug discovery with the bfLEAPu2122 platform, holding high potential within a growth market. Its smaller size and dependence on platform performance pose challenges. The company's future depends on strategic partnerships, effective marketing, and the platform's success in delivering results. Intensely competitive landscape also poses risk. Warrant valuation is inherently tied to the risk and volatility of underlying BFRG stock.
Similar Companies
NVS
Novartis AG ADR
NVS
Novartis AG ADR
RXRX
Recursion Pharmaceuticals Inc
RXRX
Recursion Pharmaceuticals Inc
SCHR
Schwab Intermediate-Term U.S. Treasury ETF
SCHR
Schwab Intermediate-Term U.S. Treasury ETF
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change. Warrants are derivatives and are more risky than stocks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-02-14 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2 | Website |
Full time employees 2 | Website | ||
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.